AlphaCentric Advisors’s Sutro Biopharma STRO Stock Holding History

AlphaCentric Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,600	Closed	-$491K	–	268
2021 Q3	$491K	Sell	2,600 -100	-4%	-$19K	0.12%	68
2021 Q2	$502K	Buy	2,700 +2,300	+575%	+$450K	0.14%	62
2021 Q1	$91K	Hold	400	–	–	0.03%	164
2020 Q4	$87K	Buy	+400	New	+$66.2K	0.04%	150

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

AlphaCentric Advisors's STRO Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Sutro Biopharma (STRO) in Q4 2021, closing a stake of 2,600 shares — an estimated $491K sold.

AlphaCentric Advisors first reported a position in STRO in Q4 2020 and held it in 4 quarters. The position peaked at $502K in Q2 2021. 117 funds tracked by Wall St. Rank hold STRO as of Q4 2021.

AlphaCentric Advisors reported no remaining Sutro Biopharma position as of Q4 2021 after selling out during the quarter.
AlphaCentric Advisors sold 2,600 Sutro Biopharma shares in Q4 2021, an estimated $491K.
AlphaCentric Advisors first reported a position in Sutro Biopharma in Q4 2020 and held it in 4 quarters.
AlphaCentric Advisors's Sutro Biopharma position peaked at $502K in Q2 2021.
117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.